Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Osmotica Pharmaceutical US LLC Identifier:
First received: November 28, 2012
Last updated: May 27, 2014
Last verified: May 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2014
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)